Share Email Print
cover

Proceedings Paper

Whole bladder wall photodynamic therapy using 5-ALA: an experimental study in pigs
Author(s): Hugo J. van Staveren; Johan F. Beek; Cess W.J. Verlaan; Annie Edixhoven; Anne E. Saarnak; Dick Sterenborg; Theo M. de Reijke; Guy Brutel de la Riviere; Sharon L. Thomsen; Martin J. C. van Gemert; Willem M. Star
Format Member Price Non-Member Price
PDF $14.40 $18.00

Paper Abstract

The agent 5-aminolevulinic acid (5-ALA) can be an alternative drug in whole bladder wall (WBW) photodynamic therapy (PDT), as its good tumor selectivity and the short time skin photosensitivity after systemic administration are advantageous for clinical use. To determine the maximum drug and light doses for reversible normal tissue damage, a pre-clinical study was performed using an in vivo normal piglet bladder model. First, the kinetics of PpIX production in 2 pigs was determined in vitro after oral administration of 75 and 150 mg/kg ALA respectively. The concentration of PpIX in plasma, and erythrocytes was determined by reversed phase high-performance liquid chromatography (HPLC) and the maximum was reached at approximately equals 5 hours after the administration of ALA. This provided a guideline for the optimum interval between ALA administration and light application. Next, various ALA doses were either administered orally or instilled in the bladder and different light doses were applied. Bladder biopsies were taken at regular intervals and normal tissue damage was investigated histologically. Reversible tissue damage was obtained using 60 mg/kg of 5-ALA in combination with a light dose of 100 J cm-2 (non-scattered plus scattered 630 nm wavelength light) in the case of oral administration. In the case of intravesical instillation, a drug dose of 2.5 gram and a light dose of 100 J cm-2 are still too high to obtain reversible tissue damage.

Paper Details

Date Published: 31 January 1996
PDF: 7 pages
Proc. SPIE 2625, Photochemotherapy: Photodynamic Therapy and Other Modalities, (31 January 1996); doi: 10.1117/12.230951
Show Author Affiliations
Hugo J. van Staveren, Daniel den Hoed Cancer Ctr. (Netherlands)
Johan F. Beek, Academic Medical Ctr. (Netherlands)
Cess W.J. Verlaan, Academic Medical Ctr. (Netherlands)
Annie Edixhoven, Dijkzgt Hospital (Netherlands)
Anne E. Saarnak, Academic Medical Ctr. (Netherlands)
Dick Sterenborg, Academic Medical Ctr. (Netherlands)
Theo M. de Reijke, Academic Medical Ctr. (Netherlands)
Guy Brutel de la Riviere, Daniel den Hoed Cancer Ctr. (Netherlands)
Sharon L. Thomsen, Univ. of Texas M.D. Anderson Cancer Ctr. (United States)
Martin J. C. van Gemert, Academic Medical Ctr. (Netherlands)
Willem M. Star, Daniel den Hoed Cancer Ctr. (Netherlands)


Published in SPIE Proceedings Vol. 2625:
Photochemotherapy: Photodynamic Therapy and Other Modalities
Benjamin Ehrenberg; Giulio Jori; Johan Moan, Editor(s)

© SPIE. Terms of Use
Back to Top